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ORIGINAL ARTICLE
Discrepancies between creatinine-based and cystatin C-based equations in estimating
prevalence of stage 3 chronic kidney disease in an elderly population
Pierre Delanaye1, Etienne Cavalier2, Annie Saint-Remy1, Laurence Lutteri2 and Jean-Marie Krzesinski1
1Department of Nephrology and 2Department of Clinical Chemistry, University of Lie`ge, CHU Sart Tilman, Lie`ge, Belgium
Background. The prevalence of stage 3 chronic kidney disease (CKD) is increasing, calculated using the
modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration rate (GFR).
Cystatin C-based equations are also being used to estimate GFR. Using creatinine-based and cystatin C-based
equations, the aim of our study was to measure the difference in prevalence of stage 3 CKD in a population.
Methods. CKD screening is organized in the Province of Lie`ge, Belgium. On a voluntary basis, people aged
between 45 and 75 years are invited for screening. GFR is estimated using the MDRD study equation and by the
three recent cystatin C-based equations proposed by Levey’s group. The Levey 1 equation is based on cystatin C
only and the Levey 2 equation on cystatin C corrected for age and sex. The Levey 3 equation combines cystatin
C, creatinine, age and sex. Results. The population screened comprised 754 people. Cystatin C is highly correlated
with creatinine (r50.6196, pv0.0001). Prevalence of stage 3 CKD when GFR is estimated by the MDRD
equation study is 17.2 %, which is significantly and much higher than the prevalence obtained when cystatin C-
based equations are used. Indeed, prevalence is 2 %, 3.3 % and 5.8 % with the Levey 1, 2 and 3 equations,
respectively. Conclusions. The prevalence of stage 3 CKD varies strongly following the method used for
estimating GFR, creatinine-based or cystatin C-based equations. Such discrepancies must be confirmed and
explained in additional studies using GFR measured with a reference method.
Keywords: Chronic kidney disease; creatinine; cystatin C; glomerular filtration rate
Introduction
The prevalence of end-stage renal failure is increasing
in Western countries [1] and, in this context,
prevention of chronic kidney disease (CKD) is
important [2]. The first step for efficient prevention
is early diagnosis, but serum creatinine is of limited
value for such a task, as it is known that creatinine
will rise above normal values only when 50 % of
glomerular filtration rate (GFR) has already been
lost [3,4]. Limitations of serum creatinine are
numerous, but its lack of sensitivity is due especially
to its relationship with muscular mass. Creatinine
therefore lacks sensitivity in populations with lower
muscular mass, notably the older population [4,5].
Several authors have proposed a creatinine-based
equation to improve GFR estimation. Today, the
modification of diet in renal disease (MDRD) study
equation is the one most used for estimating GFR
and has succeeded the older Cockcroft equation [6].
Recent epidemiological data have shown that nearly
10 % of the population in the USA have stage 3 CKD
or worse, defined as estimated GFR lower than
60 mL/min/1.73 m2. These results were obtained with
the MDRD study equation [1]. However, we and
others have emphasized that the MDRD equation is
neither accurate nor precise in estimating GFR in
healthy populations and, more obviously, when it is
applied to normal creatinine values [7–9]. There are
several good reasons for believing that the MDRD
study equation underestimates GFR (and thus over-
estimates CKD prevalence) in populations with
normal or near-normal creatinine values [7,8].
Plasma cystatin C is a relatively new marker of
GFR. Indeed, although strong physiological studies
are few in number, cystatin C is constantly produced
by all nucleated cells of the body, freely filtrated
through the glomeruli and neither reabsorbed nor
secreted by the tubules. It is fully catabolized in the
proximal tubules [10–12]. Cystatin C has been shown
of interest in the early detection of decreased kidney
function. Moreover, several equations based on
cystatin C level have been built to estimate GFR.
However, most have been elaborated from a limited
sample and have been poorly validated [10,12].
Recently, Levey’s group, which is at the origin of
the MDRD study equation, has elaborated three
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cystatin C-based equations with different variables
from a large sample of CKD patients (n52980):
Levey 1 with cystatin C as the only variable, Levey 2
including cystatin C, age, sex and race as variable and
Levey 3 including these same variables and the serum
creatinine [13]. It has been interesting to evaluate the
prevalence of CKD (defined as estimated GFR under
60 mL/min/1.73 m2) with the MDRD study equa-
tion, on the one hand, and with these three new
cystatin C-based equations, on the other.
Method
This retrospective study was driven in the context of
the CKD screening programme organized by the
Province of Lie`ge’s Health deputation. The Province
of Lie`ge, one of the 10 provinces in Belgium, covers
an area of 3862 km2 and its population from 2005
data has been calculated at 1,037,161 inhabitants.
CKD screening is organized by participants visiting a
mobile medical unit travelling through the 84
communes of the Province. On a voluntary basis,
people aged between 45 and 75 years are invited for
screening. Blood samples and anthropometrical data
are collected and a short interview is carried out. The
blood samples are sent frozen to the Clinical
Chemistry Laboratory of the University of Lie`ge
within the following 24 h. Between September and
December 2006, all the samples were frozen at 220 C˚
and in January and February 2008 they were thawed.
Serum creatinine was measured by the IDMS trace-
able enzymatic method from Roche (Crea plus;
Roche Diagnostics, Mannheim, Germany) on a
Hitachi 917. For creatinine determination, our
laboratory has been enrolled in different external
quality assessments, such as the Belgian IPH
(Institute of Public Health) and German DGKL
(Deutsche Gesellschaft fu¨r Klinische Chemie und
Laboratoriumsmedizin). This assay is also currently
accredited against the ISO 15189 Standard. Cystatin
C was measured by particle-enhanced nephelometric
immunoassay (PENIA) on the BNII nephelometer
(Siemens Healthcare Diagnostics, ex-Dade-Behring,
Marburg, Germany). This PENIA assay is the same
as the one that Levey et al. used in their study. The
equations are given in Table I. As our creatinine is
IDMS traceable, we used the new ‘‘175’’ MDRD
study equation [6].
A random spot urine was obtained and proteinuria
was researched by dipstick analysis (Combur3; Roche
Diagnostics, Mannheim, Germany). Hypertension and
diabetes were self-reported by the participants.
As the distribution of estimated GFRs
by creatinine-based equations is not normal, the
different results of estimated GFR were compared
using the Wilcoxon test. We calculated and compared
the percentage of patients with stage 3 CKD or worse
(stage 3 CKD being defined as an estimated GFR
under 60 mL/min/1.73 m2) obtained with the four
equations, and the coefficients of correlation between
the different equations were calculated. Agreement
between equations to discriminate GFR above and
below 60 mL/min/1.73 m2 was evaluated by Kappa
statistics. We also compared the results of GFR
estimated by the MDRD study equation, on the one
hand, and the results of GFR estimated by the
cystatin C-based equations, on the other, by Bland
and Altman analysis [14]. In these analyses, we
arbitrarily chose the creatinine-based equation results
as the referent. As cystatin C is not (or very little)
dependent on muscular mass, we specifically studied
a subgroup of patients based on body mass index (w
or v30 kg/m2). Bias between equations was defined
as the mean of the differences. The SD around the
mean reflects the dispersion and precision of the
equations. Pv0.05 was considered as significant. All
analyses were performed using MedCalcH (MedCalc
Software; Mariakerke, Belgium).
Results
During the study period, 754 people were screened
(48.7 % male and 51.3 % female). The anthropo-
metric, clinical and biological characteristics of the
global population are given in Table II. There is no
difference between men and women in relation to
anthropometrical and clinical data, nor are mean
creatinine and cystatin C different between the sexes.
As the Levey 1 equation does not include a sex factor
correction, there is logically no difference between
the mean values obtained with this equation in men
and women. However, mean estimated GFR is
Table I. Creatinine-based (S Cr; mg/dL) and cystatin C-
based (CC; mg/L) equations for estimating glomerular
filtration rate (GFR).
4-variable MDRD Study equation
GFR (mL/min/1.73 m2)51756SCr (mg/dL) 21.154
6Age 20.20360.742 (if woman)61.21 (if black)
Levey 1 equation
GFR (mL/min/1.73 m2)576.76CC (mg/L) 21.19
Levey 2 equation
GFR (mL/min/1.73 m2)5127.76CC (mg/L) 21.17
6Age 20.1360.91 (if woman) 61.06 (if black)
Levey 3 equation
GFR (mL/min/1.73 m2)5177.66SCr (mg/dL) 20.65
6CC (mg/L) 20.576Age 20.260.82 (if woman)
61.11 (if black)
































significantly different between the sexes (and lower in
women) when the MDRD study equations are
analysed (97¡24 versus 72¡28 mL/min/1.73 m2),
the Levey 2 (106¡24 versus 96¡20 mL/min/
1.73 m2) and the Levey 3 (105¡24 versus
86¡20 mL/min/1.73 m2).
Cystatin C is highly correlated with creatinine
(r50.6216, pv0.0001). Plasma cystatin C and serum
creatinine are correlated with age in our population
(pv0.0001), correlation being significantly higher for
cystatin C than for creatinine (r50.4096 and
r50.1960, respectively).
With the Wilcoxon test, all the estimated GFRs
are different from each other (pv0.0001). The
prevalence of stage 3 CKD when GFR is estimated
by the MDRD equation study is 17.2 %. This
prevalence is significantly much higher than that
obtained when cystatin C-based equations are used.
Indeed, the prevalences of stage 3 CKD are 2 % and
3.3 % with the Levey 1 and 2 equations, respectively
(no difference between these two equations). The
prevalence of stage 3 CKD with the combined
(creatinine and cystatin C) Levey 3 equation is
significantly (5.8 %) lower than with the MDRD
study equation, but significantly higher than with the
Levey 1 and 2 equations. Kappa statistics show poor
agreement between creatinine-based and cystatin C-
based equations for discriminating GFR under and
over 60 mL/min/1.73 m2 (kv0.2).
All equation results are highly correlated
(pv0.0001). The coefficients of correlation between
the equations are given in Table III. All the correla-
tions are statistically different, with the best correla-
tion logically seen between the Levey 1 and 2
equation results and the weakest between the
MDRD study and the Levey 1 study equation results.
The Bland and Altman analysis results are
summarized in Figure 1. The mean difference
between the MDRD study equation and the Levey
1 equation is +25.3¡24.2 mL/min/1.73 m2. The
differences with the Levey 2 and 3 equations are
+17.4¡21.5 and +11.9¡9.5 mL/min/1.73 m2, respec-
tively. The difference between the Levey 3 equations
and the MDRD study equation is lower than the
difference between the MDRD study equation and
the other two Levey equations.
In the subgroup analysis based on the BMI, we
show that the prevalence of CKD stage 3 is not
different in the obese population whatever equation is
used. In this specific subgroup (n5148), the mean
eGFR by the MDRD study equation is not different
from the global population (85¡26 versus
83¡26 mL/min/1.73 m2, respectively). This is also
the case for the Levey 3 equation (93¡24 versus
95¡24 mL/min/1.73 m2, respectively). However, for
the Levey 1 and 2 equations, the results of eGFR are
significantly lower in the obese population than in the
global population (Levey 1: 101¡22 versus
109¡23 mL/min/1.73 m2, respectively, Levey 2:
95¡22 versus 101¡23 mL/min/1.73 m2, respectively).
Discussion
Epidemiologic studies in different Western countries
have recently shown that prevalence of CKD, defined
as GFR under 60 mL/min/1.73 m2, is about 10 % in
the global population [1,15]. These data have been
obtained with the MDRD study equation using a
well-calibrated serum creatinine [16,17]. However, the
use of this equation is not free from criticism. We
have recently demonstrated that this equation tends
to underestimate GFR strongly in healthy popula-
tions and, more generally, in patients with normal or
near normal creatinine values [7,8]. Cystatin C is
thought to be a better marker of kidney function,
especially because its concentration is less influenced
by muscular mass than serum creatinine [12,18].
Several cystatin C-based equations have been pro-
posed for estimating GFR and the recent cystatin C-
based equations proposed by Levey et al. will
certainly be the most successful in the future, because
these three equations have been built from studies
Table II. Anthropometric and biological description of the
population (n5754). Data are expressed as mean ¡SD.
N5754 Mean SD
Age 61.3 8.6
Weight (kg) 74.7 14.7
Height (cm) 167 9
BMI (kg/m2) 26.6 4.3




Creatinine (mg/dL) 0.86 0.2




Levey 1 109 23
Levey 2 101 23
Levey 3 95 24
Table III. Correlation between creatinine-based and cysta-
tin C-based equations.
MDRD study Levey 1 Levey 2
MDRD Study
Levey 1 0.51
Levey 2 0.61 0.97
Levey 3 0.93 0.78 0.85
































with a large sample of patients [13]. In our population
of volunteers, the prevalence of CKD is strongly
discordant using creatinine-based or cystatin C-based
equations. Indeed, if the prevalence of stage 3 CKD is
as high as 17 % using the MDRD study equations,
the prevalence will decrease to 2 %, 3.3 % and 5.8 %
for the equations based on cystatin C concentrations
only, on cystatin C, sex and age, and on cystatin C
and creatinine concentrations sex and age, respec-
tively. It seems logical to have a less important
(although significant) difference between the results
obtained with the MDRD and the Levey 3 equation
than between the MDRD and the Levey 1 and 2
equations, as serum creatinine is part of the Levey 3
equation. From our point of view, and as other
authors have also shown, the MDRD study equation
underestimates GFR in healthy populations because
this equation has been built from a CKD population
(and the relationship between creatinine and GFR is
not the same in healthy or in CKD patients) [9,19]
and because the new factor 175 in the IDMS
traceable equation has been obtained erroneously
[7]. Moreover, the mean age of our study population
is relatively high (61¡9 years) and the accuracy and
precision of the MDRD study equation are probably
still less in aged populations with low creatinine
values [20]. Regarding the cystatin C-based equa-
tions, it may also be of interest to compare our
population with the population where the three
equations have been built. The population studied
by Levey is a CKD population (mean GFR:
48¡25 mL/min/1.73 m2) [13]. However, contrary to
creatinine, there is no reason to believe that the
relationship between cystatin C and GFR is different
in CKD and non-CKD populations. The Levey
population is an American one and our subjects are
European. The American Levey equation has still not
been validated in a European population but, using
another European built cystatin C equation [21]
(eGFR577.246CC (mg/L)21.2623), we found exactly
the same prevalence of stage 3 CKD as with the
Levey 1 equation (i.e. 1.99 %). Our population is also
older than the Levey population (61¡9 years old
versus 52¡13 years), but the influence of age seems
of limited importance as there is no difference in the
prevalence of our population using either the Levey 1
equation (using only cystatin C) or the Levey 2
equation (using cystatin C and age). Another point is
that our population has a lower BMI than in the
Levey population (27¡4 versus 29¡6 kg/m2). For
some authors, cystatin C is not strictly independent of
weight and muscular mass [18,22]. As cystatin C is
higher in heavier patients, and as our patients are
lighter than patients in the Levey study, the Levey

























































































Figure 1. Bland and Altman analysis between the MDRD
study equation and the three new Levey equations (A:
Levey 1, B: Levey 2, C: Levey 3). The continuous line
represents the mean difference between measured and
estimated GFR, whereas the dashed lines represent the
limits of agreement (mean difference¡2 SD). All values are
expressed in mL/min/1.73 m2.
































population. The prevalence of stage 3 CKD with the
cystatin C-based equations could theoretically still be
overestimated in our population.
Obesity and age are both factors of risk for CKD
[23]. However, no difference is found in stage 3 CKD
prevalence when the creatinine-based equations
(MDRD and Levey 3) are used between the global
and the obese populations. On the other hand, the
eGFR in the obese population is significantly lower
with the cystatin C-based equations than in the global
and non-obese population. This could be an indirect
argument in favour of cystatin C-based equations,
but the absence of true GFR measurement does not
permit conclusions to be drawn.
The main limitation of our study is linked to the
fact that we have not measured GFR with a
reference method. So, even if we have indirect
arguments affirming that MDRD study equations
overestimate CKD prevalence in global popula-
tions, such an assertion can only be made if a
reference method GFR is used. The new cystatin C-
based equations must also be validated against
measured GFR. In the same way, we are unable to
confirm that the combined equation (Levey 3) is
better for estimating GFR than the other two
cystatin C-based equations. Our data only underline
potential strong discrepancies between results in
epidemiological studies when cystatin C-based or
creatinine-based equations are used. Second, our
stage 3 CKD prevalence data are of interest only
because they illustrate these discrepancies. As our
population is clearly not representative of the
Belgian population (because only volunteers are
included), our stage 3 CKD prevalence results
cannot be considered epidemiologically. Thirdly,
we have no data on ethnicity. As the ethnicity factor
varies following the equations, this could be a
source of bias. However, in Belgium, Caucasians
are, by far, the dominant ethnic group. Moreover,
there is little doubt that the differences observed in
our study are not due to the ethnic factor (1.21 for
the MDRD study equation, 1.06 and 1.11 for the
Levey 2 and Levey 3 equations, respectively).
Fourthly, plasma cystatin C concentration seems
dependent on thyroid status and is influenced by
steroid therapy independently of any GFR changes.
These potential interferences have not been con-
sidered in our study [24,25]. Nevertheless, great
discrepancies between creatinine and cystatin C-
based results are certainly not fully explained by
these potential interferences. Lastly, we have
defined CKD as GFR v60 mL/min/1.73 m2. The
definition of CKD is subject to debate, however,
notably in the elderly population [26]. Whatever,
our data do not bring an end to this debate.
In conclusion, the present study illustrates large
discrepancies in the prevalence of stage 3 CKD in a
population according to the method used for
estimating GFR (creatinine-based or cystatin C-
based). We disfavour the MDRD study equations
in epidemiological studies. More research is urgently
needed to confirm and explain these discrepancies.
Population studies using GFR measurements with a
reference method are required.
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